BioMarin reported five-year PROPEL open-label extension results for POMBILITI + OPFOLDA in late-onset Pompe disease, showing durable motor function and stabilized pulmonary decline with manageable safety. The gains were larger in previously untreated patients, while ERT-experienced users demonstrated smaller but positive improvements; data were presented at the World Muscle Society Congress in Hiroshima. These long-term findings support the therapy's value proposition and could bolster investor sentiment around BioMarin's rare-disease portfolio, particularly if ongoing follow-ups continue to confirm durability.
BioMarin will acquire Alesta Therapeutics for $275 million upfront plus up to $215 million in milestones to obtain ALE1, an oral therapy for hypophosphatasia in Phase 1/2a. Alesta will spin out non-ALE1 assets pre-close, with no Alesta employees joining BioMarin. The deal is modestly dilutive to 2026 earnings ex-upfront, but could broaden BioMarin’s addressable rare-disease market.
BioMarin Pharmaceutical's (BMRN) VOXZOGO study showed a 2.33 cm/year improvement in growth velocity, exceeding market expectations and securing plans for a supplemental New Drug Application with the FDA in 2026. Analysts have largely maintained positive ratings, suggesting confidence in BMRN's future performance and potential market impact for hypochondroplasia treatments.
BioMarin Pharmaceutical reported that its experimental treatment for a rare genetic condition has met one of the primary goals in a late-stage study. This progress could enhance market confidence and attract investor interest if the results align with regulatory expectations.
BioMarin Pharmaceutical has discontinued mid-stage trials for a bone disorder treatment due to reports of hip joint dislocations, resulting in a 4% decline in share value. This decision can adversely impact BioMarin's product pipeline and future revenue prospects.
BioMarin acquires Amicus Therapeutics for $4.8 billion. The deal is expected to accelerate revenue growth immediately. Two new rare disease therapies will diversify BioMarin’s portfolio. Analysts maintain a Buy rating, boosting price forecast to $100. BMRN shows positive short-term technical momentum despite long-term challenges.
